CaliPharms Gross Profit

CaliPharms posts a gross profit of $-31K as of September 2014. In the prior-year period, the figure was $0. That is below the Industrials sector average of $120B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, CaliPharms's gross profit was $0. The latest reading is $-31K (period ending September 2014). Use the history and growth charts on this page for a longer lookback.

For Industrials stocks, a gross profit near $120B is typical. CaliPharms's $-31K is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of CaliPharms's financial statement story. At $-31K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for KGET's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $120B), and (3) consistency with growth and profitability. This page covers the first two; CaliPharms's other metric pages and overview cover the third.